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Results: Over a 5-year period, a total of 298,105 patients underwent coronary
angiography (CAG) and 176,166 patients underwent percutaneous coronary inter-
vention (PCI). Diagnosis was acute coronary syndrome (ACS) in 22%, stable
angina or silent ischemia in 23% and atypical chest pain in 9% of cases. Normal
coronary arteries or not significant coronary lesions were found in 26% of patients.
Radial access was increasingly used over the years regardless of the indication.
The average number of PCI per procedure was 1.5±0.7 (range from 1.3±0.7 to
1.5±0.7) and those of stents per procedure were 1.5±0.8 (range from 1.5±0.8 to
1.6±0.8). Drug-eluting stents (DES) were used in 45% (range from 34 to 62%).
Conclusions: Coronary anatomy is highly dependent on clinical presenta-
tion. Strategies to reduce the number of normal CAG performed for atypical
chest pain should be developed. The management of ACS is associated with
less radial access, more single PCI and fewer DES.
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Objective: The hypothesis of the study was that increased drug administra-
tion frequency [twice daily versus once daily] may provide more effective
platelet inhibition in patients with type 2 diabetes mellitus.
Methods: Twenty patients with type 2 diabetes mellitus with stable coro-
nary artery disease were prospectively recruited. All the patients received once
daily 150 mg of aspirin and clopidogrel for two weeks. Then patients were
switched to aspirin and clopidogrel 75 mg twice daily for two weeks. Pharma-
codynamic assessment was performed by VerifyNow system accumetrics at
fifteen and thirty days.
Results: There was no difference between the antiplatelet effect produced
by 150 mg of aspirin given once daily and 75 mg of aspirin given twice daily.
A twice-daily dose of 75 mg of clopidogrel is associated with significantly
more effective platelet inhibition on the residual assay: PRU=38.2% once
daily vs 53.8% twice daily (p= 0.001) and PRU=187 once daily vs 147 twice
daily (p=0.005). 
Conclusions: Increasing the frequency of clopidogrel administration to
twice daily in patients with type 2 diabetes mellitus is significantly associated
with more effective platelet inhibition. But our data do not support a twice-
daily dose of aspirin to improve platelet response.
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Background: Clopidogrel low response correlates with poor prognosis
after percutaneous coronary intervention (PCI). Many biological tests are cur-
rently available to test the clopidogrel response. However, the presence of any
correlation between the different tests is today poorly reported.
Methods: In this prospective study, clopidogrel response was assessed in
100 consecutive patients. All patients were tested between 18h and 24h after
a 600mg clopidogrel loading dose using 3 different tests: light transmission
aggregometry with 10 µmol ADP (LTA, results expressed as platelet inhibi-
tion percentage), VerifyNow-P2Y12 (VN, results expressed as PRU) and
vasodilatator stimulated phosphoprotein (VASP, results expressed as IRP).
Patients under chronic clopidogrel therapy were excluded.
Results: The mean platelet inhibition percentage, PRU value and IRP value
were 38.5±13% by LTA, 178±89 PRU by VN and 52±21% by VASP. When
results were analyzed as continuous variables, there was a good correlation
between the different tests: LTA/VN (R2=0,642, p<0,001), LTA/VASP
(R2=0,409, p<0,001) and VN/VASP (R2=0,616, p<0,001). However, when
results were analyzed as pre-specified cut-off points to define patients as “low
or good responders” (according to the literature: 50% for LTA, 235 PRU for VN
and 50% IRP for VASP), only 47% of the patients were defined as “good” or
“low responders” by the 3 tests. Altogether, 33% of the patients were defined as
“low responders” by only 1 test, 20% by 2 tests and only 16% by the 3 tests.
Conclusion: If the correlation between the different tests is good when
results are analyzed as continuous variables, each individual is rarely (less
than 50%) defined as “low or good responder” by all the 3 tests when reco-
gnized cut-off values are used. In that way, a sole test might not be sufficient
to manage antiplatelet therapy in an individual patient.
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Background: Low-molecular-weight heparins have recently been intro-
duced in the management of ST elevation myocardial infarction (STEMI)
patients but evidence remains poor among specific populations particularly
elderly and patients with renal dysfunction.
Objective: to compare the outcome (mortality and hemorrhage) between
patients treated with unfractionned heparin (UFH) versus low-molecular-
weight heparins (LMWHs) in the whole population and among elderly and
renal dysfunction patients.
Methods: Patients admitted for STEMI between January 1995 and
November 2011 were retrospectively enrolled in the MIRAMI (MonastIR
Acute Myocardial Infarction) registry. We compared the outcome (mortality
and hemorrhage) between patients who received UFH versus LMWHs in the
global MIRAMI population, then among elderly (aged over 75 years) and
renal dysfunction patients (defined by a creatinin level >130 µmol/l).
Résultats: UFH was more often used when thrombolysis was adopted as
reperfusion therapy (80.6% vs 68.6% when primary angioplasty is adopted,
p<0.001), when patients present with heart failure (p<0.001), among elderly
(p<0.001) and in patients with renal dysfunction (p=0.002). High rates of pre-
scription of UFH may be attributed to the enrollment of patients since 1995,
before LMWHs introduction in clinical practice. Mortality was higher among
patient treated with UFH. This difference was statistically significant in the
global population (11.9% vs 3.1%, p<0.001), but there was no significant dif-
ferences among elderly (22.3% and 13.3%, p=0.65) and in renal dysfunction
patients (39% vs 20%, p=0.23). Use of LMWHs did not show an increase of
hemorrhagic complications in the global population (p=0.118), among elderly
(p=0.45) nor renal dysfunction patients (p=0.61).
Conclusion: In the MIRAMI registry, LMWHs seemed to be at least as
safe and effective as UFH in STEMI patients, even in elderly or renal dys-
function population.
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Background: The national observational study of diagnostic and interven-
tional cardiac catheterization (ONACI) is a prospective multi-center registry
